L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis

The Use of L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05792527

Enrollment

Registered

2023-03-31

Start date

2023-03-05

Completion date

2026-03-05

Last updated

2023-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid arthritis via targeting Jak/STAT pathway and TGF-β1

Interventions

DRUGL-carnitine

One 500 mg tablet twice daily after meals

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria (9) i.e., 28 joints disease activity score (DAS-28) \>2.6. * Patients receive the conventional DMARDs * Both sexes. * Age range between 18 and 70 years old.

Exclusion criteria

* Patients with heart disease (congestive heart failure, arrhythmia, hypertension, ischemic heart diseases), diabetes, active infection, other illness except rheumatoid arthritis. * Patients with renal and hepatic dysfunction. * Patients receiving biological DMARDs. * Patients receiving oral prednisolone greater than 15 mg/day. * Patients with hypersensitivity to study medications. * Patients using antioxidants. * Pregnant and lactating females.

Design outcomes

Primary

Measure	Time frame	Description
The change in DAS-28-CRP score	3 months	Patients will undergo clinical assessment according to DAS-28-CRP score
The change in Multidimensional Health Assessment Questionnaire (MDHAQ) score	3 months	—

Secondary

Measure	Time frame	Description
The change in serum level of C-reactive protein (CRP)	3 months	Blood samples will be collected at base line and after 3 months
The change in serum level of Signal transducer and activator of transcription 3(STAT 3).	3 months	Blood samples will be collected at base line and after 3 months
The change in serum level of Transforming growth factor β1(TGF-β1).	3 months	Blood samples will be collected at base line and after 3 months

Countries

Egypt

Contacts

Primary ContactAbdallah A Eldisouky

PG_165476@pharm.tanta.edu.eg201279142631

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026